Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease.
Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now.
In exchange for an upfront payment, research fees and milestones as the program advances, Neurimmune will take care of generating and validating antibody candidates using its Reverse Translational Medicine (RTM) platform. For its part, Ono will take over development and commercialization of the therapy.
Neurimmune’s RTM platform employs high-throughput analysis of how the immune system of elderly people that stay particularly healthy as they age responds to disease proteins. Using this technology, the company has built a pipeline of promising candidates against neurodegenerative diseases like Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS).
Last year, the Swiss biotech participated in the launch of a new company, AL-S Pharma, that focuses on fighting ALS, a disease for which there is no cure. Read more about it in our review of biotech’s efforts to fight ALS.
Image via gameanna /Shutterstock